News Release

Elsevier launches SciVal Strata to enhance research evaluation

The tool enables institutions to establish and profile high-performance teams

Business Announcement


Amsterdam 15 March, 2011 – Elsevier, a leading publisher of scientific, technical and medical information products and services, today announced the availability of SciVal Strata ( SciVal Strata is a web-based research performance tool that offers users the flexibility to construct relevant contextual data to evaluate research teams or individual researchers, using a range of indicators based on Scopus data. SciVal Strata can be used by all members of a subscribing institution to demonstrate research excellence and to secure, allocate and measure return-on-investment of funding. The tool also improves recruitment, promotion and collaboration processes.

SciVal Strata allows researchers and decision makers throughout academic and governmental organizations to evaluate performance and demonstrate the value of research in ways that are most relevant to their career stage, field of expertise and topics of interest. Moreover, it enables users to envision alternate research groups by 'dragging and dropping' any researcher across the globe into hypothetical teams and gauge expected changes in performance by benchmarking 'fantasy' groups against existing groups. Developed in collaboration with research organizations and powered by the breadth of Scopus, SciVal Strata provides a unique context for decision-making by visualizing the performance of teams and researchers both inside and outside of an organization.

"This tool complements current methodologies used by universities and government agencies by measuring the performance of research teams and individuals in ways that were not possible before," said Jay Katzen, Managing Director of Elsevier Academic and Government Products. "SciVal Strata can help users make more informed research decisions based on relevant benchmarks and measures, such as citations or document output. This new approach will empower users to more accurately assess research performance according to criteria most important to them and help justify funding, hiring decisions and partner opportunities."


About the Elsevier SciVal® Suite

Elsevier's SciVal suite ( of services supports academic and government leadership in evaluating, establishing and executing research strategies that optimize the performance of existing assets and maximize investments to enhance near and long-term productivity. SciVal tools leverage Scopus® data, Elsevier's trusted source of bibliometric data, to offer innovative yet authoritative solutions. Current suite offerings include: SciVal Spotlight™, a strategic tool that generates unique institutional and country maps of existing and emerging strengths based on an interdisciplinary perspective of current performance; SciVal Funding™, an online solution that provides targeted recommendations on grants to pursue based on pre-populated research profiles and historical awards; SciVal Experts, a semantic technology-based application that enables researchers to identify and locate sources of expertise at an individual or departmental level within and across institutions.

About Elsevier

Elsevier is a world-leading publisher of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include SciVerse ScienceDirect, SciVerse Scopus, Reaxys, MD Consult and Nursing Consult, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.